M. V. Hauwe

发表

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

G. Comi, S. Corti, E. Mazzone, 2022, The Lancet Neurology.

Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study

M. Main, M. Sormani, E. Mazzone, 2013, Neuromuscular Disorders.

Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients

M. Main, E. Mazzone, C. Palermo, 2014, Neuromuscular Disorders.

Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial

B. Ceulemans, N. Goemans, L. Mertens, 2011, Neuromuscular Disorders.

P4.27 Fourty eight-week follow-up data from a Phase I/IIa extension study of systemic PRO051/GSK2402968 in Duchenne muscular dystrophy: Comparison with contemporaneous controls for 6-min walking distance test

N. Goemans, G. Campion, M. Tulinius, 2011, Neuromuscular Disorders.

Coordination Of Lot-Sizing Decisions In A Game Theoretical Framework Part 1

M. van den Hauwe, M. V. Hauwe, 2011 .

Test–retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5–12years

H. Feys, K. Klingels, N. Goemans, 2013, Neuromuscular Disorders.

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids

K. Klingels, N. Goemans, G. Buyse, 2013, Neuromuscular Disorders.

Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids

N. Goemans, G. Campion, M. Tulinius, 2017, Neuromuscular Disorders.

Longitudinal alterations of gait features in growing boys with Duchenne muscular dystrophy

K. Desloovere, A. Van Campenhout, A. Campenhout, 2020 .